FY4Q19 royalty revenue=$51.3M, up from $44.4M in FY3Q19 (Apr-Jun 2019).
ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year; the royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.
9/30/19 cash=$400M.
FY4Q19 GAAP EPS=$0.44.
FY2020 R&D guidance is $155-175M.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.